It is an alarming fact that AMR (AntiMicrobial Resistance) claims 23,000 Americans lives each year. This, according to a report commissioned by British Prime Minister David Cameron, could result in 10 million extra deaths a year by 2050 at a cost of $100 trillion to the global economy. How do we combat this global threat? One of the key things is to develop new antibiotics, the key theme of the World AntiMicrobial Resistance Congress this October.
Whilst there are a number of scientific and big policy conferences in the world, there are only a few that focus on the economic side. Still, none of the conferences explore other alternatives to the PPP model for developing antibiotics and none talk about vaccines, for instance, for infection prevention.
Are there other innovative and alternative ways to public-private partnerships? How can developing new antibiotics make more business sense? How can the GAIN Act be improved? Are there other incentives under way? Have infection prevention such as new vaccines been considered? Are there other ground-breaking technologies to aid in diagnosis, surveillance and prevention?
The World AntiMicrobial Resistance Congress gathers key stakeholders from government, funding agencies, pharma, academia and payers to discuss this urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions.
This 2-day conference presents solutions through key notes, case study presentations, expert opinion, roundtable discussions and invites key influencers such as BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion.
Join us in Washington D.C. this October.
Whilst there are a number of scientific and big policy conferences in the world, there are only a few that focus on the economic side. Still, none of the conferences explore other alternatives to the PPP model for developing antibiotics and none talk about vaccines, for instance, for infection prevention.
Are there other innovative and alternative ways to public-private partnerships? How can developing new antibiotics make more business sense? How can the GAIN Act be improved? Are there other incentives under way? Have infection prevention such as new vaccines been considered? Are there other ground-breaking technologies to aid in diagnosis, surveillance and prevention?
The World AntiMicrobial Resistance Congress gathers key stakeholders from government, funding agencies, pharma, academia and payers to discuss this urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions.
This 2-day conference presents solutions through key notes, case study presentations, expert opinion, roundtable discussions and invites key influencers such as BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion.
Join us in Washington D.C. this October.
